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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the eHicacy and safety of interventions for managing abdominal pain in people with Crohn's disease.
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B A C K G R O U N D
Description of the condition
Crohn's is a remitting and relapsing disease of the gastrointestinal
tract. It aHects over 3.5 million young people and adults in the
USA and Europe (Kaplan 2015). Active Crohn's disease presents
as abdominal pain, fatigue, weight loss and diarrhea. It has
no known cure, but can be managed, therefore, places a huge
financial burden on healthcare systems. The annual care costs
of irritable bowel disease (IBD) to the National Health Service
(NHS) was estimated at over GBP 1 billion in 2010 (RCP 2012). For
Crohn's disease alone, this amounts to over GBP 6000 per patient
annually (Ghosh 2015). Treatment of the disease may involve
surgical intervention or immunosuppression using thiopurines and
anti-tumor necrosis factor (anti-TNF) metabolites (Gjuladin-Hellon
2019). These interventions aim to induce remission, maintain
remission and manage the symptoms (Greenley 2013).
Abdominal pain is a common and debilitating symptom of Crohn's
and other IBDs that is multifaceted. It could be a symptom of
relapse of the disease, due to adverse eHects of medication,
surgical complications and strictures or adhesions secondary to
IBD (Srinath 2012). In the absence of the aforementioned factors,
around 20% to 50% of people with Crohn's in remission still
experience pain (Bielefeldt 2009). This has been attributed to
functional abdominal pain disorders (FAPD) such as irritable bowel
syndrome (IBS), functional abdominal pain, abdominal migraine
and functional dyspepsia (Odes 2017), although the definition of
such disorders involves the explicit exclusion of pathology such
as IBD. There is a lack of evidence to indicate whether there is a
specific variant of functional pain coexisting within people with IBD
or a separate pain disorder that can be attributed to IBD pathologic
mechanisms. The etiology and management of abdominal pain in
Crohn's disease, therefore, may vary in ways that cannot be fully
explained. It may also vary in adults and children. Finally, it may
also be influenced by disease activity.
Description of the intervention
Pharmacological interventions
Medication for Crohn's disease can reduce inflammation and
associated pain by inducing remission. Where pain persists
in the absence of inflammation, it can be managed with
pain-relieving medication such as antispasmodics, non-steroidal
anti-inflammatory drugs (NSAIDs), laxatives, antidepressants,
antiemetic agents, cyclo-oxygenase-2 inhibitors (COX-2), and
psychoactive drugs such as cannabis and opioids (Srinath 2012).
Due to potential adverse eHects of some of these drugs, short-term
use is advised.
Non-pharmacological interventions
Non-pharmacological interventions used in managing pain may
include dietary, psychological, lifestyle advice and alternative
medicine. These interventions are generally considered less
invasive and may be used as adjuvant treatment. Cognitive
behavioral therapy, stress management and coping skills training
are the most common psychological interventions used. These
are an interesting set of therapies as the specific interventions
delivered can be very heterogeneous and as such it is key to
consider the specific evidence and conceptual alignment of the
approach delivered to understand 'what' the therapy was, as
well as 'whether' it was eHective. Alternative treatments such
as acupuncture and TENS, which have been used with other
conditions such as IBS, are becoming more commonly used in
people with IBD albeit with limited evidence (Srinath 2012). Dietary
interventions studied include FODMAP (Fermentable Oligo-, Di-,
Monosaccharides And Polyols) and supplements with prebiotic
properties; however, there seems to be weak conflicting evidence
on their eHectiveness (Norton 2017).
How the intervention might work
The mechanism of action of diHerent interventions depends
on the nature or cause of the abdominal pain. Antispasmodics
suppress intestinal spasms which cause pain from inflammation
or obstruction (Srinath 2012). Pain caused by strictures can
be eliminated by the introduction of foods which can pass
through with ease thereby preventing intestinal pain (Srinath
2012). Psychological techniques such as cognitive behavioral
therapy tend to help people with Crohn's disease change negative
behaviors and provide coping mechanisms which might be
worsening their pain (Norton 2017). There are concerns around
the safety of these interventions. In addition to oHering short-
term relief, there seems to be concerns among people with IBD
about the stigma of addiction associated with the use of opioids.
The use of opioids in chronic pain can also lead to people
exhibiting withdrawal symptoms which are similar to Crohn's
disease symptoms (Pauly 2017). This may complicate further
treatment. While some interventions such as neurochemicals and
acupuncture have only been used in conditions such as IBS, others
such as COX-2 inhibitors have been associated with little to no
eHect.
Why it is important to do this review
Abdominal pain in people with Crohn's disease can lead to
depressive symptoms, a decline quality of life and an increase the
use of healthcare facilities (Srinath 2012); therefore, eHective pain
management is vital. Pain management has been highlighted as a
priority topic for research by IBD patient groups and charities, but
is currently not covered in the National Institute for Health and Care
Excellence (NICE) or European Crohn's and Colitis Organisation
(ECCO) guidelines (ECCO 2010; NICE 2019). While several non-
Cochrane systematic reviews have assessed interventions for pain
management in IBD, currently none has assessed the eHicacy and
safety of these interventions in Crohn's disease. Even though this
review covers interventions that have been previously assessed
in published Cochrane systematic reviews in the group portfolio
(Iheozor-Ejiofor 2019; Kafil 2018; Limketkai 2019; Timmer 2011), the
focus is only on studies that have been conducted for the purpose
of providing relief for abdominal pain.
O B J E C T I V E S
To assess the eHicacy and safety of interventions for managing
abdominal pain in people with Crohn's disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published, unpublished and ongoing randomised trials that
compare interventions for the management of abdominal pain
Interventions for the management of abdominal pain in Crohn's disease (Protocol)
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with other active interventions or standard therapy, placebo or
no therapy. We will exclude studies that do not report on any
abdominal pain outcomes.
Types of participants
People with Crohn's disease who are experiencing abdominal pain.
Types of interventions
• Pain-relieving drugs such as antispasmodics, antidepressants,
laxatives, antidiarrheal agents, antibiotics, analgesics, antireflux
agents, antiemetic agents, antimigraine agents, antihistaminic
agents, serotonergic agents and psychoactive drugs.
• Behavior therapy, for example, cognitive behavioral therapy,
hypnotherapy.
• Lifestyle advice, for example, advice on physical activity
including exercise.
• Dietary interventions such as FODMAP; additional fiber intake;
decrease in gas-producing foods; extra fluid intake; lactulose-,
gluten-. histamine-free diet.
• Pre- and probiotics.
• Alternative medicines, for example, acupuncture, homeopathy,
body-oriented therapy, musculoskeletal therapy (osteopathy/
chiropractic), yoga.
Types of outcome measures
Primary outcomes
• Treatment success as defined by the authors.
• Abdominal pain frequency or change in frequency of pain.
• Abdominal pain intensity or change in pain intensity using any
validated scale.
• Withdrawal due to adverse events.
Secondary outcomes
• Anxiety/depression.
• Adverse events (total of number of participants with any event)
• Serious adverse events (as defined by good clinical practice
reporting within the primary study)
Timing of outcome measurement
Where outcomes are measured at multiple time points, we will
subgroup them into three time periods: short-term (within one
month of the intervention), medium-term (more than one month
to six months) and long-term (more than six months).
Search methods for identification of studies
Electronic searches
We will search the following sources from the inception of each
database to the date of search and will place no restrictions on the
language of publication:
• Cochrane Central Register of Controlled Trials (CENTRAL) via the
Cochrane Register of Studies Online (CRSO);
• MEDLINE (Ovid MEDLINE ALL from 1946);
• PsycINFO via Ovid;
• CINAHL via EBSCO (Cumulative Index to Nursing and Allied
Health Literature);
• AMED (Allied and Complementary Medicine database) via Ovid;
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials Registry
Platform (ICTRP) (www.who.int/trialsearch/).
For detailed search strategies, see Appendix 1.
Searching other resources
As complementary search methods, we will carefully check relevant
systematic reviews for studies for potential inclusion in our review.
In addition, we will scrutinize the references of included studies in
our review. We will seek unpublished trials by contacting experts
in the field and we will scan the Internet and abstracts submitted
to major international congresses from the three years prior to the
search to capture any studies presented but not yet published in
full.
We will attempt to obtain translations of papers when necessary.
Data collection and analysis
We will carry out data collection and analysis according to the
methods recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Selection of studies
Two review authors will independently screen the titles and
abstracts identified from the literature search. We will discard
studies which do not meet the inclusion criteria. We will then obtain
the full report of studies that appear to meet our inclusion criteria or
for which there is insuHicient information to make a final decision.
Two review authors will independently assess these articles to
establish whether the studies meet the inclusion criteria. We will
resolve disagreements by discussion, with a third review author
consulted if resolution is not possible. We will enter studies rejected
at this or subsequent stages in the 'Characteristics of excluded
studies' tables and record the main reason for exclusion.
Where studies have multiple publications, we will collate the
reports of the same study so that each study, rather than each
report, is the unit of interest for the review, and such studies have a
single identifier with multiple references.
Data extraction and management
Two review authors will independently carry out data extraction
using piloted data extraction forms. We will extract the following
data from full-text articles that meet the inclusion criteria:
• trial setting: country and number of trial centers;
• methods: study design, total study duration and date;
• participant characteristics: age, sociodemographics, ethnicity,
diagnostic criteria, pain location and total number of
participants;
• eligibility criteria: inclusion and exclusion criteria;
• intervention and comparator;
• outcomes: outcome definition, unit of measurement and time of
collection;
• results: number of participants allocated to each group, missing
participants and sample size;
• funding source.
Interventions for the management of abdominal pain in Crohn's disease (Protocol)
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We will list all treatment arms in the 'Characteristics of included
studies' table.
Assessment of risk of bias in included studies
Two review authors will independently assess all studies meeting
the inclusion criteria for their risk of bias using criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). The domains will be:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective reporting (reporting bias);
• other bias such as imbalance in participants' baseline
characteristics.
We will judge the studies to be at low, high or unclear risk of bias
for each domain assessed, based on the guidance in Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
ANer data extraction, the two review authors will compare the
extracted data and discuss and resolve discrepancies before the
data are transferred into the 'Characteristics of included studies'
table. For cluster RCTs, we intend to judge risk of bias as prescribed
in Section 16.3.2 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Measures of treatment e9ect
For the dichotomous outcomes, we will express treatment eHect
as risk ratios (RR) with corresponding 95% confidence intervals
(CI). For continuous outcomes, we will express the treatment
eHect as mean diHerence (MD) with 95% CI. Where endpoint and
change score are both reported, we will use endpoint scores for
data analysis. However, if the studies assess the same continuous
outcome in diHerent ways, we will estimate the treatment eHect
using the standardized mean diHerence (SMD). We will present
SMDs as standard deviations and interpret them as follows: 0.2
represents a small eHect, 0.5 a moderate eHect and 0.8 a large eHect
(Cohen 1988).
Unit of analysis issues
The participant will be the unit of analysis. For studies comparing
more than two intervention groups, we will make multiple pair-
wise comparisons between all possible pairs of intervention
groups. To avoid double counting, we intend to divide out
shared intervention groups evenly among the comparisons. For
dichotomous outcomes, we plan to divide up both the number
of events and the total number of participants. For continuous
outcomes, we will only divide up the total number of participants
and leave the means and standard deviations unchanged. Cross-
over studies will only be included if data are separately reported
before and aNer cross-over and will use only precross-over data.
We do not anticipate finding any cluster RCTs; however, study data
will only be used if the authors have used appropriate statistical
methods in taking clustering eHect into account. We will also
exclude cluster RCTs in a sensitivity analysis to assess their impact
on the results.
Dealing with missing data
We aim to contact authors where there are missing data or studies
have not reported data in suHicient detail. We will attempt to
estimate missing standard deviations using relevant statistical
tools and calculators available in Review Manager 5 if studies
report standard errors (Review Manager 2014). Studies that fail to
report measures of variance will be judged at high risk of selective
reporting bias.
Assessment of heterogeneity
We will scrutinize studies to ensure that they are clinically
homogeneous in terms of participants, intervention, comparator
and outcome. To test for statistical heterogeneity, we will use a
Chi2 test using a P value of less than 0.1 to give an indication of
the presence of heterogeneity. Inconsistency will be quantified and
represented by the I2 statistic. The thresholds will be interpreted as
follows (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%; may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
Most reporting biases will be minimized by using an inclusive
search strategy. We will investigate publication bias using a funnel
plot if there are 10 or more studies. The magnitude of publication
bias will be determined by visual inspection of the asymmetry of
the funnel plot. In addition, we will test funnel plot asymmetry
by performing a linear regression of intervention eHect estimate
against its standard error, weighted by the inverse of the variance
of the intervention eHect estimate (Egger 1997).
Data synthesis
To summarize the study characteristics, we will conduct a narrative
synthesis of all the included studies. We will then carry out a meta-
analysis if we have two or more studies that have assessed similar
populations, interventions and outcomes. We will analyze studies
of children, adults and diHerent subintervention types separately.
We will use Review Manager 5 (Review Manager 2014). Study data
will be synthesized using the random-eHects model if there is
statistical heterogeneity (I2 greater than 0%), otherwise we will use
the fixed-eHect model. We will combine eHect estimates of studies
which report data in a similar way in the meta-analysis. We will pool
RRs for dichotomous outcomes and MDs or SMDs for continuous
outcomes alongside 95% CIs. Where we are unable to carry out a
meta-analysis (e.g. due to lack of uniformity in data reporting), we
will present a narrative summary of the included studies.
Subgroup analysis and investigation of heterogeneity
If there is heterogeneity, we will investigate possible causes and
address them using methods described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We will
undertake subgroup analyses of potential eHect modifiers if there
are 10 or more studies. We have identified several potential
modifiers of eHect:
• disease activity (active versus inactive disease);
• pain location;
Interventions for the management of abdominal pain in Crohn's disease (Protocol)
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• disease location.
It is recognized that the nature of the studies likely to be included in
this review may be heterogeneous in a number of key clinical and
methodologic ways that cannot be fully predicted. If we identify
such factors and they become relevant to ensure integrity of the
analysis, we may modify this list and report them fully.
Sensitivity analysis
Where possible, we will undertake a sensitivity analysis on the
primary outcome of 'treatment success', to assess whether the
findings of the review are robust to the decisions made during
the review process. In particular, we will exclude studies at
high or unclear risk of selection bias due to allocation bias and
performance bias, from analyses that have a mix of studies with
diHerent risk of bias judgments. Where data analyses include
studies with reported and estimated standard deviations, we
will exclude those with estimated standard deviations to assess
whether this aHects the findings of the review. We will investigate
whether the choice of model (fixed versus random) may have
aHected the results.
GRADE and 'Summary of findings' table
We will present the main results in a 'Summary of findings'
table. Each comparison and primary outcome will be exported
to GRADEprofiler soNware (developed by the GRADE Working
Group) for quality assessment (GRADEpro GDT). Data permitting,
we intend to present four 'Summary of findings' tables in the
following hierarchy: comparisons involving pain-relieving drugs,
behavioral therapy, lifestyle advice, dietary interventions, and pre-
and probiotics. Other comparisons will be graded and presented in
additional tables. Based on risk of bias, inconsistency, imprecision,
indirectness and publication bias, we will grade the quality of the
evidence for each outcome as high, moderate, low or very low.
These ratings have been defined as follows:
• high: further research is very unlikely to change our confidence
in the estimate of eHect;
• moderate: further research is likely to have an important impact
on our confidence in the estimate of eHect and may change the
estimate;
• low: further research is very likely to have an important impact
on our confidence in the estimate of eHect and is likely to change
the estimate;
• very low: any estimate of eHect is very uncertain.
We will justify all decisions to downgrade the quality of studies
using footnotes and we will make comments to aid reader's
understanding of the review where necessary.
We plan on including all 4 primary outcomes within the tables
A C K N O W L E D G E M E N T S
Funding for ZIE and partial funding for MG was provided through
a larger National Institute for Health Research (NIHR) Cochrane
Programme Grant in the UK.
Maria-Inti Metzendorf, the Information Specialist of the Cochrane
Metabolic and Endocrine Disorders Group, developed the search
strategies, which will be run by Yuhong Yuan (Information
Specialist, Cochrane Upper GI and Pancreatic Diseases Group).
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A P P E N D I C E S
Appendix 1. Search strategies
 
Cochrane Central Register of Controlled Trials (Ovid EBMR)
1. exp Pain/
2. (pain* or headache* or migraine* or fibromyalgia* or neuralgia* or colic*).tw.
3. (discomfort* or ache or aching or aches).tw.
4. or/1-3
5. Crohn Disease/
6. Inflammatory Bowel Diseases/
7. ((Crohn or Crohn*).tw.
8. (inflammatory bowel disease*).tw.
9. (enteritis or ileitis or ileocolitis or colitis).tw.
10. or/5-9
11. 4 and 10
MEDLINE (Ovid)
1. exp Pain/
2. (pain* or headache* or migraine* or fibromyalgia* or neuralgia* or colic*).tw.
3. (discomfort* or ache or aching or aches).tw.
4. or/1-3
5. Crohn Disease/
6. Inflammatory Bowel Diseases/
7. (Crohn or Crohn*).tw.
8. (inflammatory bowel disease*).tw.
9. (regional enteritis or regional ileitis or terminal ileitis or granulomatous enteritis or ileocolitis or granulomatous colitis).tw.
10. or/5-9
11. 4 and 10
[Cochrane Handbook RCT filter - sensitivity max version]
12. randomized controlled trial.pt.
13. controlled clinical trial.pt.
14. randomi?ed.ab.
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21. exp animals/ not humans/
22. 20 not 21
23. 11 and 22
[Wong 2006 – systematic reviews filter – sensitivity and specificity best balance version]
24. meta analysis.mp,pt. or review.pt. or search*.tw.
25. 11 and 24






5. (pain* or headache* or migraine* or fibromyalgia* or neuralgia* or colic*).tw.
6. (discomfort* or ache or aching or aches).tw.
7. or/1-6
8. Crohn Disease/
9. (Crohn or Crohn*).tw.
10. (inflammatory bowel disease*).tw.
11. (regional enteritis or regional ileitis or terminal ileitis or granulomatous enteritis or ileocolitis or granulomatous colitis).tw.
12. or/8-11
13. 7 and 12
[Eady 2008 "PsycInfo search strategies" filter – best sensitivity version]
14. control*.tw. OR random*.tw. OR exp Treatment/
15. 13 and 14
AMED (Ovid)
1. (pain* or headache* or migraine* or fibromyalgia* or neuralgia* or colic*).tw.
2. (discomfort* or ache or aching or aches).tw.
  (Continued)
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3. or/1-2
4. (Crohn or Crohn*).tw.
5. (inflammatory bowel disease*).tw.
6. (enteritis or ileitis or ileocolitis or colitis).tw.
7. or/4-6
8. 3 and 7
CINAHL (EBSCO)
S1. MH "Pain+"
S2. TI (pain* OR headache* OR migraine* OR fibromyalgia* OR neuralgia* OR colic*)
S3. AB (pain* OR headache* OR migraine* OR fibromyalgia* OR neuralgia* OR colic*)
S4. TI (discomfort* OR ache OR aching OR aches)
S5. AB (discomfort* OR ache OR aching OR aches)
S6. S1 OR S2 OR S3 OR S4 OR S5
S7. MH "Crohn Disease"
S8. TI (Crohn or Crohn*)
S9. AB (Crohn or Crohn*)
S10. TI (inflammatory bowel disease*)
S11. AB (inflammatory bowel disease*)
S12. TI ("regional enteritis" OR "regional ileitis" OR "terminal ileitis" OR "granulomatous enteritis" OR ileocolitis OR "granulomatous
colitis")
S13. AB ("regional enteritis" OR "regional ileitis" OR "terminal ileitis" OR "granulomatous enteritis" OR ileocolitis OR "granulomatous
colitis")
S14. S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S15. S6 AND S14
[Wong 2006 "CINAHL therapy studies" filter – best sensitivity version]
S16. MH "prognosis+" OR MH "study design+" OR random*
S17. S15 AND S16
WHO ICTRP Search Portal (Standard search)
pain* AND Crohn* OR
headache* AND Crohn* OR
migraine* AND Crohn* OR
colic* AND Crohn* OR
pain* AND inflammatory AND bowel AND disease OR
headache* AND Inflammatory AND bowel AND disease OR
  (Continued)
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migraine* AND Inflammatory AND bowel AND disease OR
colic* AND Inflammatory AND bowel AND disease OR
pain* AND enteritis* OR
headache* AND enteritis* OR
migraine* AND enteritis* OR
colic* AND enteritis* OR
pain* AND ileitis* OR
headache* AND ileitis* OR
migraine* AND ileitis* OR
colic* AND ileitis* OR
pain* AND ileocolitis* OR
headache* AND ileocolitis* OR
migraine* AND ileocolitis* OR
colic* AND ileocolitis*
ClinicalTrials.gov (Advanced search)
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